Editas Medicine is a gene editing company developing genomic medicines using CRISPR technology to treat serious diseases. The company utilizes a proprietary platform based on CRISPR/Cas9 and CRISPR/Cas12a systems to create molecules that edit DNA, with a strategic focus on in vivo gene editing and functional upregulation. Its lead development candidate, EDIT-401, is an experimental therapy designed to reduce LDL-cholesterol by upregulating the LDL receptor for the treatment of hyperlipidemia. Editas Medicine also develops in vivo gene-editing medicines targeting hematopoietic stem cells for sickle cell disease and beta thalassemia, leveraging a proprietary lipid nanoparticle delivery platform. Through partnerships, the company advances alpha-beta T-cell medicines with Bristol Myers Squibb and Juno Therapeutics for solid tumors, liquid tumors, and autoimmune diseases, and collaborates with Immatics on gamma-delta T-cell therapies for cancer. Additionally, Editas Medicine licenses its Cas9 gene editing technology to Vertex Pharmaceuticals for ex vivo gene editing medicines targeting the BCL11A gene in sickle cell disease and beta thalassemia.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage editasmedicine.com
Sector Healthcare IR page ir.editasmedicine.com
Tags
gene editing, crispr, in vivo therapy, hemoglobinopathies, hyperlipidemia, cell therapy, lipid nanoparticles, sickle cell disease, beta thalassemia, autoimmune disease, oncology, EDIT-401, renizgamglogene autogedtemcel, reni-cel, AsCas12a, Juno Therapeutics, Immatics, Vertex Pharmaceuticals, CASGEVY, exagamglogene autotemcel, DRI Healthcare Trust
Press page editasmedicine.com/newsroom

Metrics

Valuation  
Market cap $ 236.398M
Market cap (USD) $ 236.398M
P/E -4.56
PEG —
P/BV 2.80
P/S 4.74
P/OCF -2.15
P/FCF -2.14
Dividend yield —
Turnover / mcap —
Returns  
ROE -198.1%
ROI -186.3%
ROIC -139.7%
Profit margin -395.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 67.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score -88.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 40.52M 32.314M 78.123M 19.712M 25.544M 90.732M 20.531M 31.937M — — —
Net profit -160.06M -237.093M -153.219M -220.432M -192.502M -115.976M -133.746M -109.954M -120.324M -97.183M -72.9M
Free cash flow -165.848M -219.11M -136.897M -181.467M -171.78M -187.005M -46.836M -50.461M -11.476M -53.419M -6.834M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 2.05 1.27 10.13 8.87 26.55 70.11 29.61 22.75 30.73 16.23 —
Price performance 12m 0.61 -0.87 0.14 -0.67 -0.62 1.37 0.3 -0.26 0.89 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 88,000 679,000 30,000 418,000 6.05M 267,000 5.15M 10.2M 16.3M 15.2M
↳ YoY growth -91.4% +671.6% -95.6% +1,293.3% +1,346.9% -95.6% +1,827.0% +98.0% +59.7% -6.7%
↳ 5y CAGR +42.8% +24.9% +49.9% +220.8% +108.0% +20.2%
Borrowings, current (USD) — — — — — — — 0.00 5M 5M
Borrowings, non-current (USD) — — — — — — — 0.00 52.4M 53.6M
Lease liabilities (USD) — — 19.8M 29.1M 26.1M 26.4M 43.9M 36.5M 35M 18.1M
Cash and deposits (USD) 185M 147M 135M 238M 140M 204M 142M 124M 132M 147M
Right-of-use assets (USD) — — 19.5M 28.8M 25.1M 26.2M 43.6M 33.7M 32.6M 16.1M
Net debt (borrowings + leases - cash) (USD) — — — — — — — -87.1M -39.1M -69.9M
Cash flow detail
Operating cash flow (USD) -49.9M -9.42M -45.7M -40.7M -180M -164M -177M -132M -210M -165M
Purchases of property, plant and equipment (USD) -3.49M -2.06M -4.75M -6.17M -7.16M -7.98M -4.12M -4.72M -8.83M -607,000
Change in receivables (cash effect) (USD) 931,000 -591,000 649,000 -388,000 -5.63M 5.78M -4.88M -5.04M -6.08M 1.09M
Change in payables (cash effect) (USD) 3.25M -1.52M 1.78M 274,000 855,000 -1.14M 4.37M -1.49M -2.29M -2.89M
Interest paid (cash effect) (USD) -465,000 -13,000 — — — — — — — —
Share-based compensation (USD) 16.9M 23.4M 26.6M 27.2M 23.2M 43.4M 29.3M 19.8M 21.4M 10M
Operating cash flow before change in receivables (USD) -50.9M -8.83M -46.4M -40.3M -174M -170M -172M -127M -204M -166M
Free cash flow (OCF - PPE - intangibles) (USD) -53.4M -11.5M -50.5M -46.8M -187M -172M -181M -137M -219M -166M
Income detail
Research and development expense (USD) 57M 83.2M 90.7M 96.9M 158M 143M 175M 178M 199M 90M
↳ 5y CAGR +80.4% +53.0% +20.1% +16.0% +14.4% +15.5% -10.7%
Total comprehensive income (USD) -97.2M -120M -110M -134M -116M -193M -224M -149M -237M -160M
Comprehensive income to owners (USD) -97.2M -120M -110M -134M -116M -193M -224M -149M -237M -160M
Reported Mar 8, 2018 Mar 8, 2018 May 8, 2019 Feb 26, 2020 Feb 26, 2021 Feb 24, 2022 Feb 22, 2023 Mar 5, 2025 Mar 5, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia

New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C reduction maintained over 10 months supports EDIT-401's potential best-in-class profile

Second IND/CTA accepted for CD70 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas

Cash runway into second half of 2028, through and beyond key clinical readouts from Strive study

CAMBRIDGE, Mass., November 9, 2026 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2026 and provided business updates.

“We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine.

Novel targeted LNP delivery achieved in vivo CAR T cell generation resulting in therapeutically relevant B-cell depletion Jieni Xu, Stephen Sherman, Morgan Thompson, Ryan Santosh, Tallie Anne Algiere, Katerina Tsiounis, Ruhong Dong, Ramya Viswanathan, Anshul Gupta, Hank Lin, Ratnesh Joshi, Urmi Chheda, Harry An, Linda Burkly, Jenny Xie

See poster P0781 for tLNP manufacturing process, Second Floor, Foyer D-F

Editas Medicine, Cambridge, MA, USA

Introduction

P0361

Methods

Background ▸Chimeric antigen receptor (CAR) T-cell therapies have seen significant medical advancement in oncology and are achieving breakthrough clinical efficacy in autoimmune diseases Challenges ▸Implementation of CAR-based autoimmune therapy remains limited, partly due to the difficulties of ex vivo CAR T-cell manufacturing, which constrains scalability and accessibility Editas’ Immune Cell Targeted LNP for In Vivo CAR T-Cell Therapy Lead T-Cell Targeted LNP

• “Cargo-ready” flexibility for swapping mRNA cargos of choice • Targeting moieties changeable for cell-specificity of choice

*Anti-CD20 CAR payload was used as a surrogate because of the lack of CD19 cross-reactivity between human and NHP.

Purification

Binder Conjugation

Formulation Development T Cells

tLNPs

CAR T Cells

CAR Expression

PBMCs

B-Cell Killing

CAR Expression B-Cell Depletion in Blood and Spleen

tLNP Injection

2–3 weeks

24 hours

Humanized Mice Study

Pretreat

tLNP

Pretreat

tLNP

Necropsy Flow Cytometry

Proprietary Formulation • Optimized composition for liver de-targeting and increases plasma circulation • Highly specific and scalable conjugation chemistry

Process Improvement for Scalable Manufacturing Mixing

NSG Mouse Humanization with hPBMCs

✓ Re-dosable ✓ Off-the-shelf ✓ Transient and rapid ✓ Deep B-cell depletion ✓ No lympho-depletion

Modular Delivery Platform

Binder Screening for T Cell Targeting

In Vitro Potency Analysis

Advantages of Editas’ In Vivo CAR T-Cell Therapy with anti-CD19 CAR*

High potency, CD8-targeted LNP composition that integrates Editas’ proprietary technology

LNP Composition Optimization for Liver De-targeting

D-7

D-4

D-1

D0

D2

D3

D5 Necropsy

Non-human Primate Study

Immunohistochemistry

Results Anti-CD8/CD20 CAR tLNP Proof of Delivery Demonstrated by DoseDependent CAR Expression in NHP CD8+ T Cells in Peripheral Blood

Deep B-Cell Depletion in NHP Lymph Nodes at 0.3 mg/kg

B-Cell Depletion of ≥99% in NHP Peripheral Blood with Doses as Low as 0.1 mg/kg

Well Tolerated in NHP with No ALT/AST Elevation Relative to Vehicle

0.1 mg/kg

0.75 mg/kg

0.3 mg/kg

B-Cell Depletion of ≥99% in NHP Peripheral Blood, Bone Marrow, and Spleen with Dose as Low as 0.1 mg/kg

Anti-CD8/CD19 CAR tLNP Demonstrated Dose-Dependent CAR Expression and B-Cell Depletion in Humanized Mice

CD20 IHC

Bone Marrow

Spleen

PBS

0.1 mg/kg

0.3 mg/kg

0.75 mg/kg

-99.3%

-99.9%

-100%

-99.7%

-100%

-100%

20x

Conclusions • • •

CONCLUSIONS

We demonstrated robust in vivo delivery of mRNA to targeted T cells with our novel, scalable tLNP-based platform Transient expression of the CAR in targeted T cells resulted in deep B-cell depletion in the blood within 24 hours post-dose Therapeutically relevant B-cell depletion in lymphoid tissues was also observed, creating the potential for clinically meaningful immune reset for autoimmune therapy Disclosures Authors are employees of Editas Medicine. This study was sponsored by Editas Medicine. Acknowledgments Medical writing and editorial services have been funded by Editas Medicine and provided by Amanda Weber, RPh, of Porterhouse Medical US.

Presented at the European Society of Gene & Cell Therapy Annual Congress ● 27–30 October 2026 ● Hamburg, Germany

Abbreviations ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAR, chimeric antigen receptor; hPBMC, human peripheral blood mononuclear cell; HRP, horseradish peroxidase; IHC, immunohistochemistry; IgG, immunoglobulin G; IV, intravenous; LN, lymph node; LNP, lipid nanoparticle; PEG, polyethylene glycol; PBMC, peripheral blood mononuclear cell; PBS, phosphate buffered saline; NHP, non-human primate; NSG, NOD/SCID/IL-2Rγ −/−; mRNA, messenger RNA; scFvs, single-chain variable fragments; tLNP, targeted LNP. © 2026 Editas Medicine

Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeutics Harry An, Jieni Xu, Urmi Chheda, Stephen Sherman, Ratnesh Joshi, Yosif Yoqub, Ryan Santosh, Francis Awokang, Tallie Anne Algiere, Pam Wang, Ramya Viswanathan, Jenny Xie, Gregory Whitehead, Mercedes Segura Editas Medicine, Cambridge, MA, USA

Introduction

P0781

See poster P0361 for non-human primate data, Ground floor, Foyer 4

LNP Manufacturing Process and Analytics

▸ LNP platform: Lipid nanoparticles are a clinically proven delivery system established for liver-directed targeting across mRNA vaccines, siRNA, and gene-editing medicines (Figure 1) ▸ Challenge: Extending that platform from passive liver delivery to targeted extrahepatic tissues raises manufacturing complexity and demands tighter process control ▸ Process design: Modular architecture enables flexible scaling, streamlined technology transfer, and seamless transition from development to GMP-compliant manufacturing (Figure 2) ▸ Consistency: The resulting process maintains particle size, polydispersity index, encapsulation, and conjugation from 10 mg to 100 mg and across different binders (Figure 3), with potency retained through 5 freeze/thaw cycles (Figure 4)

Figure 1. Targeted LNP structure

▸ Case study: Applied to chimeric antigen receptor (CAR) mRNA delivery to T cells, the platform gives scale-independent potency in vitro (Figure 5) and dose-dependent CAR expression and B-cell depletion in vivo in NSG mice (Figure 6) Figure 2. tLNP process and analytics In this modular architecture design, the overall manufacturing process is composed of discrete, standardized unit operations, each performing a specific function.

Consistent Process Performance and tLNP Product Quality

Figure 3. Particle quality for tLNP batches at various scales using different binders

Figure 4. tLNP stability through freeze/thaw cycles* *F/T1, F/T3, and F/T5 indicate following 1, 3, or 5 freeze/thaw cycles, respectively.

Case Study: Immune Cell Targeting Efficacy In Vitro Potency

In Vivo Potency

Figure 5. CAR expression (left) and mean fluorescence intensity (right) of T cells transfected by tLNP batches

Figure 6. CAR frequency (left) and B-cell depletion (right) in the spleen of NSG mice treated with 2 different doses of tLNPs

Conclusions • Modular platform enables rapid evaluation of novel binders and cargos • Consistent tLNP quality attributes were maintained across scales, binders, and batches • Potency was maintained through multiple freeze/thaw cycles, demonstrating robust formulation stability Disclosures Authors are employees of Editas Medicine. This study was sponsored by Editas Medicine. Acknowledgments Medical writing and editorial services have been funded by Editas Medicine and provided by Amanda Weber, RPh, of Porterhouse Medical US. Presented at the European Society of Gene & Cell Therapy Annual Congress ● 27–30 October 2026 ● Hamburg, Germany

• A case study targeting immune cells demonstrated consistent in vitro and in vivo performance pre- and post-scale-up • The efficacy of the tLNP was demonstrated through in vivo mouse studies with robust generation of CAR T cells as well as potent B-cell depletion

Abbreviations CAR, chimeric antigen receptor; DLS, dynamic light scattering; F/T, freeze/thaw cycle; GMP, good manufacturing practice; gRNA, guide RNA; hPBMC, human peripheral blood mononuclear cell; LNP, lipid nanoparticle; NSG, NOD/SCID/IL-2Rγ −/−; mRNA, messenger RNA; PBS, phosphate-buffered saline; PEG, polyethylene glycol; siRNA, small interfering RNA; tLNP, targeted lipid nanoparticle.

© 2026 Editas Medicine

Prompts

Editas Medicine, Inc. (ticker EDIT), listed in United States.

ETFs Holding Editas Medicine, Inc.

ETF Weight in ETF Shares Market value As of
MEDX 0.47% 27,680 $ 89.683K Jun 30, 2026
NXTE 0.35% 61,197 $ 198.278K Jun 30, 2026
FSEG 0.07% 1,165 $ 3,774.60 Jun 30, 2026
FSEV 0.05% 940 $ 3,045.60 Jun 30, 2026
RESM 0.01% 166 $ 537.84 Jun 30, 2026
AVUS 0.00% 76,212 $ 142.516K Nov 16, 2026
AVSU 0.00% 755 $ 1,411.85 Nov 16, 2026